Non-Proliferative Diabetic Retinopathy Market Analysis in 2025: Identifying Opportunities and Challenges

 Created for forward-thinking professionals, this report equips teams with the insights needed to compete effectively in the non-proliferative diabetic retinopathy space.

 

 What Is The Current Outlook For The Non-Proliferative Diabetic Retinopathy Market By 2025?
 The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.83 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.
 
 The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
 
 What Are The Key Driving Factors For The Growth Of The Non-Proliferative Diabetic Retinopathy Market?
 The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose (blood sugar) due to inadequate production of insulin by the pancreas or the body’s cells becoming resistant to the effects of insulin. Diabetes is caused due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, resulting in vision impairment and potential blindness. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.
 
 Global Non-Proliferative Diabetic Retinopathy Market Report Segmentation
 The non-proliferative diabetic retinopathymarket covered in this report is segmented — 
 
 1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
 2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
 
 Subsegments:
 1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin); Ranibizumab (Lucentis); Aflibercept (Eylea); Pegaptanib (Macugen) 
 2) By Intraocular Steroid Injection: Triamcinolone Acetonide; Dexamethasone Implant (Ozurdex); Fluocinolone Acetonide Implant (Iluvien) 
 3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Photocoagulation 
 4) By Vitrectomy: Pars Plana Vitrectomy (Ppv); Membrane Peeling Vitrectomy; Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
 
 What Are The Key Trends And Market Opportunities In The Non-Proliferative Diabetic Retinopathy Sector?
 Major companies operating in the non-proliferative diabetic retinopathy market are developing AI-enabled cameras to improve patient outcomes and advance the field of ophthalmic imaging. AI-enabled cameras in ophthalmic imaging refer to devices equipped with artificial intelligence (AI) algorithms that assist in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, launched Optomed Aurora AEYE, a handheld AI fundus camera designed to detect more than mild diabetic retinopathy instantly. This innovative device combines the portability of a handheld camera with the power of artificial intelligence to provide high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images. This enables quick and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
 
 Who Are The Leading Players In The Non-Proliferative Diabetic Retinopathy Market?
 Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd. 
 
 View the full non-proliferative diabetic retinopathy market report here:
 https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report
 
 Which Region Is Projected To Hold The Largest Market Share In The Global Non-Proliferative Diabetic Retinopathy Market By 2029?
 North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company